1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. News
  7. Summary
    CYAD   BE0974260896

CELYAD ONCOLOGY SA

(CYAD)
  Report
Real-time Euronext Bruxelles  -  05/20 04:30:47 am EDT
1.750 EUR   +11.46%
05/17Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
AQ
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05CELYAD ONCOLOGY SA : Proxy Statments
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celyad Oncology : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating

08/06/2021 | 09:06am EDT


© MT Newswires 2021
All news about CELYAD ONCOLOGY SA
05/17Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
AQ
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05CELYAD ONCOLOGY SA : Proxy Statments
CO
05/05CELYAD ONCOLOGY SA : 1st quarter results
CO
04/01CELYAD ONCOLOGY SA : Ordinary general shareholder meeting
CO
03/25TRANSCRIPT : Celyad Oncology SA, 2021 Earnings Call, Mar 25, 2022
CI
03/25CELYAD ONCOLOGY : Reports Full Year 2021 Financial Results and Recent Business Highlights ..
PU
03/25CELYAD ONCOLOGY : Letter to Shareholders – March 2022
PU
03/24Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/24Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
AQ
More news
Analyst Recommendations on CELYAD ONCOLOGY SA
More recommendations
Financials
Sales 2022 7,27 M 7,70 M 7,70 M
Net income 2022 -34,7 M -36,8 M -36,8 M
Net cash 2022 9,67 M 10,2 M 10,2 M
P/E ratio 2022 -1,16x
Yield 2022 -
Capitalization 35,5 M 37,6 M 37,6 M
EV / Sales 2022 3,55x
Capi. / Sales 2023 4,02x
Nbr of Employees 98
Free-Float 60,2%
Chart CELYAD ONCOLOGY SA
Duration : Period :
Celyad Oncology SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELYAD ONCOLOGY SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,57 €
Average target price 11,00 €
Spread / Average Target 601%
EPS Revisions
Managers and Directors
Filippo Joseph Petti Director, Chief Executive & Financial Officer
Michel E. Lussier Chairman
Frederic Lehmann VP-Clinical Development & Medical Affairs
David Gilham Chief Scientific Officer
Peggy Sotiropoulou Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CELYAD ONCOLOGY SA-55.33%38
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418